MX2018016038A - Compuestos y metodos para modular la funcion del acido ribonucleico (arn). - Google Patents

Compuestos y metodos para modular la funcion del acido ribonucleico (arn).

Info

Publication number
MX2018016038A
MX2018016038A MX2018016038A MX2018016038A MX2018016038A MX 2018016038 A MX2018016038 A MX 2018016038A MX 2018016038 A MX2018016038 A MX 2018016038A MX 2018016038 A MX2018016038 A MX 2018016038A MX 2018016038 A MX2018016038 A MX 2018016038A
Authority
MX
Mexico
Prior art keywords
methods
compounds
rna function
modulating rna
modulating
Prior art date
Application number
MX2018016038A
Other languages
English (en)
Inventor
C Petter Russell
W Bair Kenneth
Kumaravel Gnanasambandam
Gregory Barsoum James
Original Assignee
Arrakis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrakis Therapeutics Inc filed Critical Arrakis Therapeutics Inc
Publication of MX2018016038A publication Critical patent/MX2018016038A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars

Abstract

La presente invención se refiere a compuestos, composiciones de los mismos, y métodos para usar los mismos.
MX2018016038A 2016-07-01 2017-06-30 Compuestos y metodos para modular la funcion del acido ribonucleico (arn). MX2018016038A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662357654P 2016-07-01 2016-07-01
US201762453487P 2017-02-01 2017-02-01
PCT/US2017/040514 WO2018006074A2 (en) 2016-07-01 2017-06-30 Compounds and methods for modulating rna function

Publications (1)

Publication Number Publication Date
MX2018016038A true MX2018016038A (es) 2019-05-13

Family

ID=60786563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018016038A MX2018016038A (es) 2016-07-01 2017-06-30 Compuestos y metodos para modular la funcion del acido ribonucleico (arn).

Country Status (11)

Country Link
US (2) US20190194150A1 (es)
EP (1) EP3478842A4 (es)
JP (1) JP2019523242A (es)
CN (1) CN109563515A (es)
AU (1) AU2017290894A1 (es)
CA (1) CA3028446A1 (es)
IL (2) IL263943A (es)
MX (1) MX2018016038A (es)
RU (1) RU2018145144A (es)
SG (1) SG11201811643TA (es)
WO (1) WO2018006074A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3230473B1 (en) 2014-12-08 2020-04-29 The Regents Of The University Of Michigan Non-coding rnas and uses thereof
BR122020005073A2 (pt) 2017-08-04 2020-10-13 Skyhawk Therapeutics, Inc. Composto, composição farmacêutica e uso do composto
EP3714043A4 (en) 2017-11-22 2021-08-11 The Regents of The University of Michigan COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
IL297543A (en) 2017-11-30 2022-12-01 Arrakis Therapeutics Inc Nucleic acid-binding photoprobes and their uses
CN113164622A (zh) * 2018-03-23 2021-07-23 怀特黑德生物医学研究所 通过调节凝聚物来调节基因转录的方法和测定
WO2019199733A1 (en) * 2018-04-10 2019-10-17 The Regents Of The University Of Michigan Compositions and methods for treating cancer
US20200017514A1 (en) * 2018-07-12 2020-01-16 Michael Plewe Adamantane derivatives for the treatment of filovirus infection
CN109928933B (zh) * 2019-01-10 2021-02-26 安徽昊帆生物有限公司 2-氯-5-醛基嘧啶及其制备方法
KR20210135241A (ko) 2019-02-05 2021-11-12 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
JP2022519523A (ja) 2019-02-08 2022-03-24 デューポイント セラピューティクス， インコーポレイテッド 化合物の凝縮物に関連する特性を特性評価する方法およびその使用
US20220073910A1 (en) * 2019-02-12 2022-03-10 The Scripps Research Institute A Cross-Linking Approach to Map Small Molecule-RNA Binding Sites in Cells
CA3153010A1 (en) 2019-09-18 2021-03-25 Dewpoint Therapeutics, Inc. Methods of screening for condensate-associated specificity and uses thereof
CN110782945B (zh) * 2019-10-22 2023-07-18 长沙学院 一种利用间接与直接特征信息识别lncRNA与疾病关联的方法
WO2023094412A1 (de) * 2021-11-25 2023-06-01 Merck Patent Gmbh Materialien für elektronische vorrichtungen
WO2023205694A2 (en) * 2022-04-20 2023-10-26 Tacit Therapeutics, Inc. Stabilization of therapeutic trans-splicing rna molecules in human cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028808A1 (en) * 2000-10-06 2002-04-11 Kansas State University Research Foundation Triptycene analogs
US9150612B2 (en) * 2007-02-23 2015-10-06 The Research Foundation Of State University Of New York RNA targeting compounds and methods for making and using same
US9260476B2 (en) * 2007-02-23 2016-02-16 The Research Foundation For The State University Of New York RNA targeting compounds and methods for making and using same
FR2968302B1 (fr) * 2010-12-06 2012-11-30 Biomerieux Sa Procedes de fonctionalisation et reactifs utilises dans de tels procedes utilisant un anhydride isatoique ou un de ses derives, molecules biologiques ainsi traitees et kits
DK2670404T3 (en) * 2011-02-02 2018-11-19 Univ Princeton CIRCUIT MODULATORS AS VIRUS PRODUCTION MODULATORS
US20180265911A1 (en) * 2015-09-24 2018-09-20 The Trustees Of The University Of Pennsylvania Triptycene derivatives for nucleic acid junction stabilization
EP3411080A4 (en) * 2016-02-01 2019-08-14 Arrakis Therapeutics, Inc. COMPOUNDS AND METHODS FOR TREATING RNA-MEDIATED DISEASES

Also Published As

Publication number Publication date
IL263943A (en) 2019-01-31
EP3478842A2 (en) 2019-05-08
SG11201811643TA (en) 2019-01-30
WO2018006074A2 (en) 2018-01-04
AU2017290894A1 (en) 2019-01-17
JP2019523242A (ja) 2019-08-22
US20220402883A1 (en) 2022-12-22
IL285229A (en) 2021-09-30
RU2018145144A (ru) 2020-08-03
US20190194150A1 (en) 2019-06-27
WO2018006074A3 (en) 2018-02-15
EP3478842A4 (en) 2020-04-15
RU2018145144A3 (es) 2020-09-14
CA3028446A1 (en) 2018-01-04
CN109563515A (zh) 2019-04-02

Similar Documents

Publication Publication Date Title
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2021006154A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
ZA202107931B (en) Anti-tau antibodies and methods of use
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
MX2019012431A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2018005292A (es) Inhibidores de acc y usos de los mismos.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MX2019007021A (es) Anticuerpos il-11ra.
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
MY191581A (en) Anti-pd-1 antibodies
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MY184870A (en) Immunomodulators
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2020013630A (es) Analogos de rapamicina y usos de los mismos.